title: Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711.
authors.affiliation: Department of Urology and Population Health, New York University and Manhattan Veterans Affairs Medical Center, New York, New York. Electronic address: stacyloeb@gmail.com.
authors.forename: Stacy
authors.initials: S
authors.lastname: Loeb
authors.affiliation: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Mats
authors.initials: M
authors.lastname: Lambe
authors.affiliation: Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå; Department of Urology, Uppsala University Hospital, Uppsala, Sweden.
authors.forename: Pär
authors.initials: P
authors.lastname: Stattin
mesh_terms: D007172:Erectile Dysfunction; D006801:Humans; D008297:Male; D008545:Melanoma; D058986:Phosphodiesterase 5 Inhibitors; D012306:Risk; D012878:Skin Neoplasms
chemical_list: D058986:Phosphodiesterase 5 Inhibitors